CoChat
Sign Up
Cited by 50Immune Response and InflammationNF-κB Signaling PathwaysInflammasome and immune disorders

Inositol Polyphosphate Multikinase Promotes Toll-like Receptor-Induced Inflammation by Stabilizing TRAF6

Open access
Kim, Eunha, Beon, Jiyoon, Lee, Seulgi, Park, Seung Ju, Ahn, Hyoungjoon, Kim, Min Gyu, Park, Jeong Eun, Kim, Wooseob +6 more·2017·Science Advances
DOI 10.1126/sciadv.1602296PMC PMC5400429
Open this paper in CoChat — free account

Abstract

Inositol polyphosphate multikinase acts as a key determinant of inflammation by stabilizing the signaling adaptor TRAF6.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.1602296

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • IPMK is implicated in neurodegeneration, cancer, and inflammation.

    “Over two decades, multidisciplinary research has unveiled its far-reaching biological roles and implications in diverse diseases, including neurodegeneration, cancer, and inflammation.”

    From From Obscurity to Prominence: IPMK’s Expanding Role in Cellular Signaling, Physiology, and Disease (2025) · cites this paper as [29]

    The Introduction and Results describe IPMK’s role in Toll-like receptor–induced inflammation, and the Discussion reports effects in mouse models of sepsis and endotoxemia. Although the Introduction describes IPMK as a signaling hub, our copy does not establish the claimed implications in neurodegeneration or cancer (searched for both). Page numbers were not available in the indexed passages. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • IPMK is involved in inflammatory disorders, obesity, Alzheimer's disease, inflammatory bowel disease, and intestinal neuroendocrine tumors.

    “Over the past two decades, research utilizing animal models and human mutation analyses has revealed IPMK’s involvement in a wide array of human diseases, including inflammatory disorders [28,29], obesity [30,31], Alzheimer’s disease [32], inflammatory bowel disease [33,34], and intestinal neuroendocrine tumors [35].”

    From From Obscurity to Prominence: IPMK’s Expanding Role in Cellular Signaling, Physiology, and Disease (2025) · cites this paper as [29]

  • IPMK binds to TRAF6 and stabilizes it by impeding its proteasomal degradation, thereby activating NF-kB downstream.

    “IPMK binds to TRAF6 and stabilizes it by impeding its proteasomal degradation, thereby activating NF-kB downstream [29].”

    From From Obscurity to Prominence: IPMK’s Expanding Role in Cellular Signaling, Physiology, and Disease (2025) · cites this paper as [29]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 61

  1. [1]Akira S., Takeda K., Kaisho T., Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat. Immunol. 2, 675– 680 (2001). 11477402
  2. [2]Kawai T., Adachi O., Ogawa T., Takeda K., Akira S., Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11, 115– 122 (1999). 10435584
  3. [3]Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J.-i., Cao Z., Matsumoto K., The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398, 252– 256 (1999). 10094049
  4. [4]Sato S., Sanjo H., Takeda K., Ninomiya-Tsuji J., Yamamoto M., Kawai T., Matsumoto K., Takeuchi O., Akira S., Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 6, 1087– 1095 (2005). 16186825
  5. [5]Gottipati S., Rao N. L., Fung-Leung W.-P., IRAK1: A critical signaling mediator of innate immunity. Cell. Signal. 20, 269– 276 (2008). 17890055
  6. [6]Pauls E., Nanda S. K., Smith H., Toth R., Arthur J. S. C., Cohen P., Two phases of inflammatory mediator production defined by the study of IRAK2 and IRAK1 knock-in mice. J. Immunol. 191, 2717– 2730 (2013). 23918981 PMC3849919
  7. [7]Medzhitov R., Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135– 145 (2001). 11905821
  8. [8]Akira S., Uematsu S., Takeuchi O., Pathogen recognition and innate immunity. Cell 124, 783– 801 (2006). 16497588
  9. [9]Beutler B., Jiang Z., Georgel P., Crozat K., Croker B., Rutschmann S., Du X., Hoebe K., Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu. Rev. Immunol. 24, 353– 389 (2006). 16551253
  10. [10]Kawai T., Akira S., The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 11, 373– 384 (2010). 20404851
  11. [11]Newton K., Dixit V. M., Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol. 4, a006049 (2012). 22296764 PMC3282411
  12. [12]Kondo T., Kawai T., Akira S., Dissecting negative regulation of Toll-like receptor signaling. Trends Immunol. 33, 449– 458 (2012). 22721918
  13. [14]Pickart C. M., Targeting of substrates to the 26S proteasome. FASEB J. 11, 1055– 1066 (1997). 9367341
  14. [15]Hjerpe R., Rodríguez M. S., Alternative UPS drug targets upstream the 26S proteasome. Int. J. Biochem. Cell Biol. 40, 1126– 1140 (2008). 18203645
  15. [16]Mattiroli F., Sixma T. K., Lysine-targeting specificity in ubiquitin and ubiquitin-like modification pathways. Nat. Struct. Mol. Biol. 21, 308– 316 (2014). 24699079
  16. [17]Deng L., Wang C., Spencer E., Yang L., Braun A., You J., Slaughter C., Pickart C., Chen Z. J., Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351– 361 (2000). 11057907
  17. [18]Lamothe B., Besse A., Campos A. D., Webster W. K., Wu H., Darnay B. G., Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of IκB kinase activation. J. Biol. Chem. 282, 4102– 4112 (2007). 17135271 PMC3221607
  18. [19]Lomaga M. A., Yeh W.-C., Sarosi I., Duncan G. S., Furlonger C., Ho A., Morony S., Capparelli C., Van G., Kaufman S., van der Heiden A., Itie A., Wakeham A., Khoo W., Sasaki T., Cao Z., Penninger J. M., Paige C. J., Lacey D. L., Dunstan C. R., Boyle W. J., Goeddel D. V., Mak T. W., TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015– 1024 (1999). 10215628 PMC316636
  19. [20]Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K., Akira S., Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-κB and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol. 171, 4304– 4310 (2003). 14530355
  20. [21]Gohda J., Matsumura T., Inoue J.-i., Cutting edge: TNFR-associated factor (TRAF) 6 is essential for MyD88-dependent pathway but not toll/IL-1 receptor domain-containing adaptor-inducing IFN-β (TRIF)-dependent pathway in TLR signaling. J. Immunol. 173, 2913– 2917 (2004). 15322147
  21. [22]Walsh M. C., Kim G. K., Maurizio P. L., Molnar E. E., Choi Y., TRAF6 autoubiquitination-independent activation of the NFκB and MAPK pathways in response to IL-1 and RANKL. PLOS ONE 3, e4064 (2008). 19112497 PMC2603309
  22. [23]Xia Z.-P., Sun L., Chen X., Pineda G., Jiang X., Adhikari A., Zeng W., Chen Z. J., Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 461, 114– 119 (2009). 19675569 PMC2747300
  23. [24]Cohen P., The TLR and IL-1 signalling network at a glance. J. Cell Sci. 127, 2383– 2390 (2014). 24829146 PMC4038938
  24. [25]Walsh M. C., Lee J., Choi Y., Tumor necrosis factor receptor-associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system. Immunol. Rev. 266, 72– 92 (2015). 26085208 PMC4799835
  25. [26]Trompouki E., Hatzivassiliou E., Tsichritzis T., Farmer H., Ashworth A., Mosialos G., CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 424, 793– 796 (2003). 12917689
  26. [27]Boone D. L., Turer E. E., Lee E. G., Ahmad R.-C., Wheeler M. T., Tsui C., Hurley P., Chien M., Chai S., Hitotsumatsu O., McNally E., Pickart C., Ma A., The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Immunol. 5, 1052– 1060 (2004). 15334086
  27. [28]Wertz I. E., O’Rourke K. M., Zhou H., Eby M., Aravind L., Seshagiri S., Wu P., Wiesmann C., Baker R., Boone D. L., Ma A., Koonin E. V., Dixit V. M., De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430, 694– 699 (2004). 15258597
  28. [29]Harhaj E. W., Dixit V. M., Regulation of NF-κB by deubiquitinases. Immunol. Rev. 246, 107– 124 (2012). 22435550 PMC3540820
  29. [30]Panda S., Nilsson J. A., Gekara N. O., Deubiquitinase MYSM1 regulates innate immunity through inactivation of TRAF3 and TRAF6 complexes. Immunity 43, 1– 13 (2015). 26474655
  30. [31]Zhou L., Ma Q., Shi H., Huo K., NUMBL interacts with TRAF6 and promotes the degradation of TRAF6. Biochem. Biophys. Res. Commun. 392, 409– 414 (2010). 20079715
  31. [32]Muroi M., Tanamoto K.-i., IRAK-1-mediated negative regulation of Toll-like receptor signaling through proteasome-dependent downregulation of TRAF6. Biochim. Biophys. Acta 1823, 255– 263 (2012). 22033459
  32. [33]Zhao W., Wang L., Zhang M., Yuan C., Gao C., E3 ubiquitin ligase tripartite motif 38 negatively regulates TLR-mediated immune responses by proteasomal degradation of TNF receptor-associated factor 6 in macrophages. J. Immunol. 188, 2567– 2574 (2012). 22323536
  33. [34]Lin X.-W., Xu W.-C., Luo J.-G., Guo X.-J., Sun T., Zhao X.-L., Fu Z.-J., WW domain containing E3 ubiquitin protein ligase 1 (WWP1) negatively regulates TLR4-mediated TNF-α and IL-6 production by proteasomal degradation of TNF receptor associated factor 6 (TRAF6). PLOS ONE 8, e67633 (2013). 23799152 PMC3684580
  34. [35]Zeng K.-W., Liao L.-X., Lv H.-N., Song F.-J., Yu Q., Dong X., Li J., Jiang Y., Tu P.-F., Natural small molecule FMHM inhibits lipopolysaccharide-induced inflammatory response by promoting TRAF6 degradation via K48-linked polyubiquitination. Sci. Rep. 5, 14715 (2015). 26423026 PMC4589686
  35. [36]Saiardi A., Erdjument-Bromage H., Snowman A. M., Tempst P., Snyder S. H., Synthesis of diphosphoinositol pentakisphosphate by a newly identified family of higher inositol polyphosphate kinases. Curr. Biol. 9, 1323– 1326 (1999). 10574768
  36. [37]Frederick J. P., Mattiske D., Wofford J. A., Megosh L. C., Drake L. Y., Chiou S.-T., Hogan B. L. M., York J. D., An essential role for an inositol polyphosphate multikinase, Ipk2, in mouse embryogenesis and second messenger production. Proc. Natl. Acad. Sci. U.S.A. 102, 8454– 8459 (2005). 15939867 PMC1150869
  37. [38]Resnick A. C., Snowman A. M., Kang B. N., Hurt K. J., Snyder S. H., Saiardi A., Inositol polyphosphate multikinase is a nuclear PI3-kinase with transcriptional regulatory activity. Proc. Natl. Acad. Sci. U.S.A. 102, 12783– 12788 (2005). 16123124 PMC1200306
  38. [39]Blind R. D., Suzawa M., Ingraham H. A., Direct modification and activation of a nuclear receptor-PIP2 complex by the inositol lipid kinase IPMK. Sci. Signal. 5, ra44 (2012). 22715467 PMC3395721
  39. [40]Kim S., Kim S. F., Maag D., Maxwell M. J., Resnick A. C., Juluri K. R., Chakraborty A., Koldobskiy M. A., Cha S. H., Barrow R., Snowman A. M., Snyder S. H., Amino acid signaling to mTOR mediated by inositol polyphosphate multikinase. Cell Metab. 13, 215– 221 (2011). 21284988 PMC3042716
  40. [41]Bang S., Kim S., Dailey M. J., Chen Y., Moran T. H., Snyder S. H., Kim S. F., AMP-activated protein kinase is physiologically regulated by inositol polyphosphate multikinase. Proc. Natl. Acad. Sci. U.S.A. 109, 616– 620 (2012). 22203993 PMC3258619
  41. [42]Kim E., Tyagi R., Lee J.-Y., Park J., Kim Y.-r., Beon J., Chen P. Y., Cha J. Y., Snyder S. H., Kim S., Inositol polyphosphate multikinase is a coactivator for serum response factor-dependent induction of immediate early genes. Proc. Natl. Acad. Sci. U.S.A. 110, 19938– 19943 (2013). 24248338 PMC3856792
  42. [43]Xu R., Paul B. D., Smith D. R., Tyagi R., Rao F., Khan A. B., Blech D. J., Vandiver M. S., Harraz M. M., Guha P., Ahmed I., Sen N., Gallagher M., Snyder S. H., Inositol polyphosphate multikinase is a transcriptional coactivator required for immediate early gene induction. Proc. Natl. Acad. Sci. U.S.A. 110, 16181– 16186 (2013). 24043835 PMC3791727
  43. [44]Xu R., Sen N., Paul B. D., Snowman A. M., Rao F., Vandiver M. S., Xu J., Snyder S. H., Inositol polyphosphate multikinase is a coactivator of p53-mediated transcription and cell death. Sci. Signal. 6, ra22 (2013). 23550211 PMC4108196
  44. [45]Monserrate J. P., York J. D., Inositol phosphate synthesis and the nuclear processes they affect. Curr. Opin. Cell Biol. 22, 365– 373 (2010). 20359876
  45. [46]Chakraborty A., Kim S., Snyder S. H., Inositol pyrophosphates as mammalian cell signals. Sci. Signal. 4, re1 (2011). 21878680 PMC3667551
  46. [47]Kawagoe T., Takeuchi O., Takabatake Y., Kato H., Isaka Y., Tsujimura T., Akira S., TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat. Immunol. 10, 965– 972 (2009). 19668221 PMC2910115
  47. [48]Maag D., Maxwell M. J., Hardesty D. A., Boucher K. L., Choudhari N., Hanno A. G., Ma J. F., Snowman A. S., Pietropaoli J. W., Xu R., Storm P. B., Saiardi A., Snyder S. H., Resnick A. C., Inositol polyphosphate multikinase is a physiologic PI3-kinase that activates Akt/PKB. Proc. Natl. Acad. Sci. U.S.A. 108, 1391– 1396 (2011). 21220345 PMC3029688
  48. [49]Seeds A. M., Tsui M. M., Sunu C., Spana E. P., York J. D., Inositol phosphate kinase 2 is required for imaginal disc development in Drosophila. Proc. Natl. Acad. Sci. U.S.A. 112, 15660– 15665 (2015). 26647185 PMC4697392
  49. [50]Häcker H., Vabulas R. M., Takeuchi O., Hoshino K., Akira S., Wagner H., Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor–associated factor (TRAF) 6. J. Exp. Med. 192, 595– 600 (2000). 10952730 PMC2193231
  50. [51]Akira S., Takeda K., Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499– 511 (2004). 15229469
  51. [52]Beutler B., Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430, 257– 263 (2004). 15241424
  52. [53]Cao Z., Xiong J., Takeuchi M., Kurama T., Goeddel D. V., TRAF6 is a signal transducer for interleukin-1. Nature 383, 443– 446 (1996). 8837778
  53. [54]Ye H., Arron J. R., Lamothe B., Cirilli M., Kobayashi T., Shevde N. K., Segal D., Dzivenu O. K., Vologodskaia M., Yim M., Du K., Singh S., Pike J. W., Darnay B. G., Choi Y., Wu H., Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418, 443– 447 (2002). 12140561
  54. [55]Yuk J.-M., Shin D.-M., Lee H.-M., Kim J.-J., Kim S.-W., Jin H. S., Yang C.-S., Park K. A., Chanda D., Kim D.-K., Huang S. M., Lee S. K., Lee C.-H., Kim J.-M., Song C.-H., Lee S. Y., Hur G. M., Moore D. D., Choi H.-S., Jo E.-K., The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors. Nat. Immunol. 12, 742– 751 (2011). 21725320
  55. [56]Schneider M., Zimmermann A. G., Roberts R. A., Zhang L., Swanson K. V., Wen H., Davis B. K., Allen I. C., Holl E. K., Ye Z., Rahman A. H., Conti B. J., Eitas T. K., Koller B. H., Ting J. P.-Y., The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-κB. Nat. Immunol. 13, 823– 831 (2012). 22863753 PMC3721195
  56. [57]Ko R., Park J. H., Ha H., Choi Y., Lee S. Y., Glycogen synthase kinase 3β ubiquitination by TRAF6 regulates TLR3-mediated pro-inflammatory cytokine production. Nat. Commun. 6, 6765 (2015). 25828701 PMC4396377
  57. [58]Jiao S., Zhang Z., Li C., Huang M., Shi Z., Wang Y., Song X., Liu H., Li C., Chen M., Wang W., Zhao Y., Jiang Z., Wang H., Wong C. C. L., Wang C., Zhou Z., The kinase MST4 limits inflammatory responses through direct phosphorylation of the adaptor TRAF6. Nat. Immunol. 16, 246– 257 (2015). 25642822
  58. [59]Rittirsch D., Huber-Lang M. S., Flierl M. A., Ward P. A., Immunodesign of experimental sepsis by cecal ligation and puncture. Nat. Protoc. 4, 31– 36 (2009). 19131954 PMC2754226
  59. [60]Mauer J., Chaurasia B., Goldau J., Vogt M. C., Ruud J., Nguyen K. D., Theurich S., Hausen A. C., Schmitz J., Brönneke H. S., Estevez E., Allen T. L., Mesaros A., Partridge L., Febbraio M. A., Chawla A., Wunderlich F. T., Brüning J. C., Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat. Immunol. 15, 423– 430 (2014). 24681566 PMC4161471
  60. [61]Choi J., Park S., Biering S. B., Selleck E., Liu C. Y., Zhang X., Fujita N., Saitoh T., Akira S., Yoshimori T., Sibley L. D., Hwang S., Virgin H. W., The parasitophorous vacuole membrane of Toxoplasma gondii is targeted for disruption by ubiquitin-like conjugation systems of autophagy. Immunity 40, 924– 935 (2014). 24931121 PMC4107903
  61. [62]Emmerich C. H., Cohen P., Optimising methods for the preservation, capture and identification of ubiquitin chains and ubiquitylated proteins by immunoblotting. Biochem. Biophys. Res. Commun. 466, 1– 14 (2015). 26325464 PMC4709362

Cited by

Sorted by citations

Authors
Kim, E., Beon, J., Lee, S., Park, S. J., Ahn, H., Kim, M. G., Park, J. E., Kim, W., Yuk, J.-M., Kang, S.-J., Lee, S.-H., Jo, E.-K., Seong, R. H., & Kim, S.
Affiliations
  • Korea Advanced Institute of Science and Technology (KR)
  • Seoul National University (KR)
  • Chungnam National University (KR)
Corresponding author
  • Seong, Rho Hyun
  • Kim, Seyun
ORCID
Venue
Science Advances
Publisher
American Association for the Advancement of Science (AAAS)
Published
2017-04-07
Volume
3
Issue
4
Pages
e1602296-e1602296
ISSN
2375-2548 (ISSN-L)
DOI
10.1126/sciadv.1602296
PMC
PMC5400429
OpenAlex
W2606838756
Cited by
50
References
1
Citations by year
2026: 5 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 7 · 2020: 2 · 2019: 6 · 2018: 2 · 2017: 3
FWCI
1.61
Type
journal article
Language
en
Open access
Locations
  • Science Advances (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
National Research Foundation of Korea (ID0ETVBI14926, NRF-2013M3C7A1056102)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Keywords
inositol polyphosphate multikinase, TRAF6, Toll-like receptor signaling, protein stability, K48-linked ubiquitination, proteasomal degradation, lipopolysaccharide-induced inflammation, polymicrobial sepsis, macrophages, innate immunity, inflammatory cytokines
MeSH terms
Animals, Macrophages, Mice, Mutant Strains, Signal Transduction, Phosphotransferases (Alcohol Group Acceptor), Proteasome Endopeptidase Complex, TNF Receptor-Associated Factor 6, Toll-Like Receptors, Mice, Ubiquitination, Protein Stability, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review